Crown BioScience, Inc., a cancer-focused CRO, has closed a $28.8 million Series C round of financing. CrownBio is headquartered in California with labs in Beijing and Taicang City. The company will use the proceeds to expand services in its core cancer drug discovery and translational oncology services, and it will also fund initiatives that expand the company’s services into other therapeutic areas. More details....

Share this with colleagues: